Search Results

Displaying Results 1-2 of 2 "'NOVN'"

Feb 17, 2026, 17:31 ET Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight

2036.Leading juvenile idiopathic arthritis companies, such as Bristol-Myers Squibb (NYSE: BMY), UCB Biopharma (EBR: UCB), Novartis (SWX: NOVN), and others, are developing new juvenile idiopathic arthritis treatment drugs that can be available in the juvenile idiopathic arthritis market in

More news about: DelveInsight Business Research, LLP


Feb 10, 2026, 17:31 ET PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight

do not go on to develop metastatic disease.Leading PROTAC companies, such as Arvinas (NASDAQ: ARVN), Pfizer (NYSE: PFE), Novartis (SWX: NOVN), Astellas Pharma (TYO: 4503), Dialectic Therapeutics, and others, are developing novel PROTAC that can be available in the PROTAC market in the

More news about: DelveInsight Business Research LLP


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.